Amber Bahr
Overview
Explore the profile of Amber Bahr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
329
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marasco M, Kumar D, Seale T, Borrego S, Kaplun E, Aricescu I, et al.
Cell Rep Med
. 2024 Nov;
5(11):101818.
PMID: 39488215
Neurofibromin (NF1) is a negative regulator of RAS signaling, frequently mutated in cancer. NF1-mutant melanoma is a highly malignant tumor for which targeted therapies are lacking. Here, we use biochemical...
2.
Biswas N, Bahr A, Howard J, Bonin J, Grazda R, MacNamara K
Stem Cell Reports
. 2024 Apr;
19(5):639-653.
PMID: 38608679
Sepsis survivors exhibit immune dysfunction, hematological changes, and increased risk of infection. The long-term impacts of sepsis on hematopoiesis were analyzed using a surgical model of murine sepsis, resulting in...
3.
Russell J, Fanchon L, Alwaseem H, Molina H, ODonoghue I, Bahr A, et al.
Pharmacol Res Perspect
. 2022 Mar;
10(2):e00898.
PMID: 35257504
Previously published digital autoradiography of H-labeled capecitabine reveals a near-uniform distribution of activity throughout a murine pancreatic model. This is in contrast both to C-labeled gemcitabine, and established expectations, as...
4.
Zhao Y, Murciano-Goroff Y, Xue J, Ang A, Lucas J, Mai T, et al.
Nature
. 2021 Nov;
599(7886):679-683.
PMID: 34759319
Inactive state-selective KRAS(G12C) inhibitors demonstrate a 30-40% response rate and result in approximately 6-month median progression-free survival in patients with lung cancer. The genetic basis for resistance to these first-in-class...
5.
Chan J, Quintanal-Villalonga A, Gao V, Xie Y, Allaj V, Chaudhary O, et al.
Cancer Cell
. 2021 Oct;
39(11):1479-1496.e18.
PMID: 34653364
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, respectively). To define the heterogeneity...
6.
Russell J, Grkovski M, ODonoghue I, Kalidindi T, Pillarsetty N, Burnazi E, et al.
J Nucl Med
. 2020 Jul;
62(2):195-200.
PMID: 32646874
F-FAC (2'-deoxy-2'-F-fluoro-β-d-arabinofuranosylcytosine) has close structural similarity to gemcitabine and thus offers the potential to image drug delivery to tumors. We compared tumor F-FAC PET images with C-gemcitabine levels, established ex...